ABT-751 in Treating Young Patients With Refractory Solid Tumors
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop tumor
cells from dividing so they stop growing or die.
PURPOSE: This phase I trial is studying the side effects of ABT-751 in treating young
patients with refractory solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)